Miyahara T, Hamanaka K, Weber DS, Anghelescu M, Frost JR, King JA, Parker JC. Cytosolic phospholipase A 2 and arachidonic acid metabolites modulate ventilator-induced permeability increases in isolated mouse lungs. J Appl Physiol 104: 354-362, 2008. First published November 15, 2007 doi:10.1152/japplphysiol.00959.2006.-We previously reported that the cytosolic phospholipase A 2 (cPLA2) pathway is involved in ventilator-induced lung injury (VILI) produced by high peak inflation pressures (PIP) (J Appl Physiol 98: 1264 -1271, but the relative contributions of the various downstream products of cPLA 2 on the acute permeability response were not determined. Therefore, we investigated the role of cPLA 2 and the downstream products of arachidonic acid metabolism in the high-PIP ventilationinduced increase in vascular permeability. We perfused isolated mouse lungs and measured the capillary filtration coefficient (K fc) after 30 min of ventilation with 9, 25, and 35 cmH 2O PIP. In high-PIP-ventilated lungs, K fc increased significantly, 2.7-fold, after ventilation with 35 cmH 2O PIP compared with paired baseline values and low-PIP-ventilated lungs. Also, increased phosphorylation of lung cPLA 2 suggested enzyme activation after high-PIP ventilation. However, treatment with 40 mg/kg arachidonyl trifluoromethyl ketone (an inhibitor of cPLA 2) or a combination of 30 M ibuprofen [a cyclooxygenase (COX) inhibitor], 100 M nordihydroguaiaretic acid [a lipoxygenase (LOX) inhibitor], and 10 M 17-octadecynoic acid (a cytochrome P-450 epoxygenase inhibitor) prevented the high-PIPinduced increase in K fc. Combinations of the inhibitors of COX, LOX, or cytochrome P-450 epoxygenase did not prevent significant increases in Kfc, even though bronchoalveolar lavage levels of the COX or LOX products were significantly reduced. These results suggest that multiple mediators from each pathway contribute to the acute ventilator-induced permeability increase in isolated mouse lungs by mutual potentiation. capillary permeability; ventilator-induced lung injury; cyclooxygenase; lipoxygenase; leukotrienes; cytochrome P-450 THE ACUTE RESPIRATORY DISTRESS syndrome (ARDS) network study has demonstrated the importance of a reduced tidal volume in preventing ventilator-induced lung injury (VILI) produced by high peak inflation pressures (PIP) and tidal volumes (7). Elevated levels of cytosolic phospholipase A 2 (cPLA 2 ), leukotrienes (LTs), and cyclooxygenase (COX) products have been reported in bronchoalveolar lavage fluid (BALF) from ARDS patients (11, 26) . In animal models, microvascular permeability is acutely increased after only 20 min of high-PIP ventilation, whereas proinflammatory cytokine production was delayed and variable (36, 45). Inhibition of cPLA 2 with arachidonyl trifluoromethyl ketone (ATK) prevented VILI in Clara cell secretory protein-knockout and wild-type mice (46) and in mice with endotoxin-induced lung injury (24). These results support the concept of a rapid onset of increased capillary permeability in response to lung overdistension mediated by rapid signal transduction through the cPLA 2 pathways. Protein leak and edema may then contribute to release of cytokines and propagation of inflammation that further increase lung injury (31, 45, 46) . Activated cPLA 2 can have myriad proinflammatory effects by catalyzing the hydrolysis of phospholipids to lysophospholipids (17), platelet-activating factor (PAF) (13), and arachidonic acid (AA) (3). AA is further metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P-450 epoxygenase (P-450) pathways to inflammatory mediators such as prostaglandins (PG), thromboxanes (TXs), LTs, and epoxyeicosatrienoic acids (EETs) (47). Inhibition of cPLA 2 may attenuate VILI by reducing these numerous downstream products, which can increase vascular permeability, recruit neutrophils, and injure cells (23). We recently identified the transient receptor potential vanilloid-4 (TRPV4) channel as the stretchactivated cation channel that initiates VILI (15). These channels are activated by PLA 2 -derived AA and its P-450 derivatives. However, the relative contributions of the specific downstream products of AA to the rapid initial permeability increase in high-PIP injury remain to be identified.
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In the present study, we used specific inhibitors of cPLA 2 activity and the activities of each of the major downstream enzymatic pathways of AA metabolism to investigate the contributions of cPLA 2 activity and the endogenously produced downstream products of AA metabolism to the acute vascular permeability response to high-PIP ventilation in isolated perfused mouse lungs. Acute changes in vascular permeability were evaluated using the capillary filtration coefficient (K fc ), a sensitive index of capillary hydraulic conductivity, as well as BALF albumin concentration, lung wet-to-dry weight ratios (W/D), and histological examination. Our data demonstrate that cPLA 2 inhibition significantly attenuated the increase in K fc after high-pressure ventilation, but only a combination of all pathway inhibitors significantly attenuated the increased permeability. These findings suggest that multiple downstream products regulated by the cPLA 2 pathway modulate the VILI-induced increase in acute microvascular permeability.
College of Medicine. Anesthetized mice were killed by exsanguination at the time of heart and lung removal.
Isolated lung preparations. C57BL/6 male mice [n ϭ 65, 17.5-26.6 (23.3 Ϯ 0.23) g; Jackson Laboratory] were anesthetized with pentobarbital sodium (100 mg/kg ip). The trachea was cannulated, and the lungs were ventilated with 20% O 2-5% CO2-75% N2 by a rodent ventilator (model 683, Harvard, South Natick, MA). The tidal volume was adjusted to obtain ϳ9 cmH 2O PIP at a respiratory rate (RR) of 40 breaths/min. The chest was opened, heparin (100 IU) was injected into the left ventricle, and a suture was placed around the pulmonary artery and aorta. Cannulas (0.86 mm ID, 1.27 mm OD) were placed in the pulmonary artery and left atrium, and the lungs and heart were removed en bloc and suspended from a balance beam attached to a force transducer (model FT03C, Grass, Quincy, MA). Plastic drapes around the preparation eliminated weight artifacts caused by air currents. The initial 1-2 ml of perfusate, which contained residual blood cells and plasma, were discarded and not recirculated. To exclude binding of each inhibitor to proteins in the perfusate, all lungs were perfused with 1% BSA-3% clinical-grade dextran 70 in Krebs bicarbonate buffer (2) via a roller pump (Minipuls2, Gilson, Middleton, WI) at a constant flow rate of 0.75 ml/min in a recirculating system with a system volume of 10 ml. Temperature was maintained at 37°C by a heating tape. The venous outflow was collected in a reservoir, the height of which could be adjusted to increase venous pressure. Pulmonary arterial (P pa), pulmonary venous (Ppv), and airway pressures were measured with a pressure transducer (Cobe, Lakewood, CO) that was zeroed at the midlung level, and pressures and lung weight were recorded on a polygraph (model 7D, Grass).
Pulmonary vascular resistances. Total resistance (R t) and segmental pulmonary vascular resistance were calculated from the perfusate flow and the differences between P pa, Ppv, and double-occlusion capillary pressure (Ppc) as follows: Rt ϭ (Ppa Ϫ Ppv)/(Q /100 g), precapillary resistance (Ra) ϭ (Ppa Ϫ Ppc)/(Q /100 g), and postcapillary resistance (Rv) ϭ (Ppc Ϫ Ppv)/(Q /100 g), where Q is perfusate flow. All resistance was normalized to predicted lung weight (i.e., cmH 2O 
is a sensitive measurement of endothelial hydraulic conductivity in fully recruited lungs (33) . After an isogravimetric state is attained, P pv was increased by 6 cmH2O for 20 min (Fig. 1) , and the change in capillary pressure was determined by double occlusion before and after the Ppv increase. Kfc was calculated as the rate of lung weight gain between 18 and 20 min divided by the change in P pc. All Kfc values were normalized to 100 g predicted lung weight on the basis of the ratio of lung weight to body weight (BW) according to predicted lung weight (PLW) as follows: PLW ϭ (0.00452 Ϯ 0.0003)BW (30) .
Isolated lung protocols. The time course for venous pressure and PIP of the high-and low-PIP-ventilation groups are shown in Fig. 1 Treatment groups. The lungs were randomly allocated to one of the following 10 groups.
Group 1 (low-PIP control group, n ϭ 6) was ventilated with 9 cmH 2O PIP and 2.5 cmH2O PEEP throughout the experiments. Group 2 (high-PIP injury group, n ϭ 10) was ventilated with the high-PIP protocol only. Group 3 (ATK group, n ϭ 9) was ventilated with the high-PIP protocol after pretreatment 30 min before the first K fc measurement with ATK (40 mg/kg body wt), an inhibitor of cPLA2 (46) . Group 4 (COX group, n ϭ 4) was ventilated with the high-PIP protocol after pretreatment with 30 M ibuprofen, a COX inhibitor (2) . Group 5 (LOX group, n ϭ 4) was ventilated with the high-PIP protocol after pretreatment with 100 M nordihydroguaiaretic acid, an LOX inhibitor (22) . Group 6 (P-450 group, n ϭ 4) was ventilated with the high-PIP protocol after pretreatment with 10 M 17-octadecynoic acid, a P-450 inhibitor (2) .
Some lungs were treated with a combination of two or three inhibitors as follows. Group 7 (COX ϩ LOX group, n ϭ 6) was ventilated with the high-PIP protocol after pretreatment with the COX and LOX inhibitors described above. Group 8 (LOX ϩ P-450 group, n ϭ 6) was ventilated with the high-PIP protocol after pretreatment with the LOX and P-450 inhibitors described above. Group 9 (COX ϩ P-450 group, n ϭ 6) was ventilated with the high-PIP protocol after pretreatment with the COX and P-450 inhibitors described above. Group 10 (COX ϩ LOX ϩ P-450 group, n ϭ 10) was ventilated with the high-PIP protocol after pretreatment with all three inhibitors for COX, LOX, and P-450 described above. These inhibitors were added to the perfusate 30 min before PIP ventilation for 30 min at 25 cmH2O.
BALF protein and AA metabolites. The right lung was lavaged four times with 0.5 ml of PBS. Albumin concentrations were measured with an ELISA (Bethyl, Montgomery, TX). Concentrations of 6-keto-PGF1␣, the stable metabolite of PGI2, and the cysteinyl LTs (LTC4, LTD4, and LTE4) were also measured using ELISA kits (Cayman Chemical, Ann Arbor, MI).
W/D. At the end of the experiments, the left lung was tied at the left hilum and then removed. The wet weight of the left lung was recorded, and the lung was desiccated at 80°C for 1 wk before dry weight was measured for W/D.
Western analysis for phosphorylated cPLA2. For protein extraction, tissue samples were minced and sonicated, cells were lysed in ice-cold buffer (in mM: 50 HEPES, 5 EDTA, 100 NaCl) at 4°C for 1 h (pH 7.4), 1% Triton X-100, protease inhibitors (10 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml leupeptin), and phosphatase inhibitors (in mM: 50 sodium fluoride, 1 sodium orthovanadate, 10 sodium pyrophosphate, and 0.001 microcystin). Solubilized proteins were isolated by centrifugation at 27,000 g for 15 min, and protein concentrations of the supernatant were determined using the Bradford assay. For Western analysis, samples were boiled in 1ϫ SDS buffer, separated using SDS-PAGE, and subsequently transferred to nitrocellulose membranes. Membranes were blocked at room temperature for 1 h in TBS containing 5% milk and 0.1% Tween 20. Lung homogenates were also separated into membrane-bound (hydrophobic) and cytosolic (hydrophilic) proteins with use of a Mem-PER protein extraction kit (Pierce Biotechnology, Rockford, IL) and probed for phosphorylated cPLA2. Primary antibodies to phosphorylated (Ser 505 ) cPLA2 and total cPLA2 were obtained from Cell Signaling (Danvers, MA). After incubation with primary and second- ary antibodies, proteins were detected by enhanced chemiluminescence, and band intensities were quantified using Sigmagel software.
Histology. A portion of the right lung was ligated and sectioned for histological examination. Sections were fixed in 10% buffered formalin, embedded in paraffin, cut with a microtome to 5 m thickness, and stained with hematoxylin and eosin. Slides were viewed by a blinded referee using light microscopy for histological evaluation of injury. Light microscopy in glutaraldehyde-fixed lungs was used to evaluate quantitative edema distribution in perivascular cuffs. In 1-m-thick sections, extra-alveolar vessel cuff volume (V c) fraction of total wall volume (Vc/Vw) was determined using a point-counting strategy (1) . Point-counting analysis was performed in four experiments in each of the low-PIP control, high-PIP injury, and ATK groups and three experiments in the COX ϩ LOX ϩ P-450 group. Means for vessel diameter and volume fractions were determined for each lung, and overall descriptive statistics were derived for each group.
Statistical analysis. Values are means Ϯ SE. A one-or two-way ANOVA with repeated measures followed by Student-NewmanKeuls or Fisher's least significant difference post hoc test was used as indicated for comparison of groups. Significant differences were determined by P Ͻ 0.05. Figure 2 shows the effects of each inhibitor combination on K fc in isolated perfused lungs. In the high-PIP injury group, K fc increased significantly, 2.7-fold, from baseline after high-PIP ventilation 80 min after baseline K fc , but K fc was not significantly increased 30 min after baseline K fc . K fc was also significantly higher in the high-PIP injury group than in the low-PIP control, ATK, and COX ϩ LOX ϩ P-450 groups. Pretreatment with ATK significantly attenuated the increase in the final K fc compared with the high-PIP injury group, although K fc in the ATK group was significantly higher than baseline K fc . This indicates that ATK did not completely prevent the increase in permeability induced by high-PIP ventilation. Also, the final K fc of all except the low-PIP control group was significantly increased compared with paired baseline K fc values. Use of a single inhibitor in the COX, LOX, or P-450 experiments or a combination of two inhibitors in the COX ϩ LOX, COX ϩ P-450, or LOX ϩ P-450 experiments did not significantly attenuate the K fc increase compared with the untreated high-PIP injury group. Only the combination of all three inhibitors in the COX ϩ LOX ϩ P-450 group significantly attenuated the high-PIPinduced increase in permeability to the same degree observed in the ATK group. Relative to the high-PIP injury group, the final K fc values were 30% for the low-PIP control group, 46% for the ATK group, and 49% for the COX ϩ LOX ϩ P-450 group. Table 1 summarizes lung W/D and albumin concentrations in BALF. Since W/D was dependent on vascular pressure and time of filtration, as well as K fc , these variables proved less sensitive than K fc to differences in permeability. Although W/D was significantly greater in all groups, except the ATK group, than in the low-PIP control group, W/D in the high-PIP injury and COX ϩ LOX ϩ P-450 groups was not significantly different from W/D in the ATK group. However, W/D of the ATK group was not significantly different from that of the low-PIP control group. Relative to the high-PIP injury group, final W/D was 80% for the low-PIP control group, 93% for the ATK group, and 94% for the COX ϩ LOX ϩ P-450 group. BALF albumin concentration was significantly lower (34%) in the ATK group than in the high-PIP injury group and significantly lower than in all other groups, except the low-PIP control group. BALF albumin was also significantly lower (19%) in the COX ϩ LOX ϩ P-450 group than in the high-PIP injury group. There was also a significant difference between the COX ϩ LOX ϩ P-450 group and the LOX, COX ϩ LOX, and COX ϩ P-450 groups. Relative to the high-PIP injury group, the final BALF albumin concentrations were 48% for the low-PIP control group, 50% for the ATK group, and 62% for the COX ϩ LOX ϩ P-450 group. Taken together, these measurements demonstrated that ATK and the combination of COX, LOX, and P-450 inhibitors significantly attenuated the increased permeability induced by high-PIP ventilation.
RESULTS

Microvascular permeability.
Pulmonary hemodynamics. Pulmonary hemodynamics of all groups are shown in Table 2 . There were no differences in baseline hemodynamics between groups. Ventilation and measurement of K fc resulted in a small decrease in R t in all groups at 50 min. R t , and especially R v , decreased significantly at the end of experiment in the low-PIP control group. Resistance of the other groups tended to increase from baseline values at the end of the experiments.
Phosphorylation of cPLA 2 . Western blots of lung tissue homogenates demonstrated a significant, 2.2-fold, increase in phosphorylated cPLA 2 after high-PIP ventilation compared with low-PIP ventilation (Fig. 3A) . The total cPLA 2 was not significantly different between groups. Separation of the homogenates into cytosol and membrane components indicated a significant, 1.8-fold, increase in membrane-associated phosphorylated cPLA 2 and a trend toward an increase in phosphorylated cPLA 2 in the high-PIP ventilation group (Fig. 3B) .
BALF AA metabolites. AA metabolites in BALF were determined using an ELISA (Fig. 4) . Lavage concentrations of 6-keto-PGF 1␣ were significantly lower in all groups, except the LOX ϩ P-450 group, than in the high-PIP injury group (Fig.  3A) . Lavage concentrations of the cysteinyl LTs were signifi- cantly lower in all groups, except the COX and COX ϩ P-450 groups, than in the high-PIP injury group (Fig. 3B) . Thus COX and LOX pathway products were significantly increased by high-PIP ventilation compared with low-PIP ventilation for the same periods. As expected, mean values of the COX or LOX pathway products tended to be lower in the groups treated with the COX or LOX inhibitors.
Histological findings. Microscopic examinations were performed on all groups, but only micrographs from the low-PIP control, high-PIP injury, ATK, and COX ϩ LOX ϩ P-450 groups are shown in Fig. 5A . Sloughing of epithelial cells was not observed in any group. Since all lungs were perfused with buffer, no differences in inflammatory cell numbers were observed. The major feature shown by light microscopy was perivascular edema cuffs, primarily around arteries and, to a lesser extent, around veins. Perivascular edema cuffs were large and prevalent in the high-PIP injury group but small and infrequent in the low-PIP control group, but more regions of atelectasis were observed in the low-PIP control group than the other groups. The cuff sizes were generally smaller and less frequent in the ATK and COX ϩ LOX ϩ P-450 groups than in the groups treated with one or two of the inhibitors. Figure  5B shows a morphometric analysis of V c /V w for four groups. Point-counting analysis was performed for four experiments in each of the low-PIP control, high-PIP injury, and ATK groups and three experiments in the COX ϩ LOX ϩ P-450 group. The number of cuffs, mean vessel diameter, and maximum and minimum diameters were n ϭ 49, 59 Ϯ 6 m, and 158 -25 m for the low-PIP control group; n ϭ 55, 57 Ϯ 4 m, and 137-25 m for the high-PIP injury group; n ϭ 17, 72 Ϯ 9 m, and 163-25 m for the COX ϩ LOX ϩ P-450 group; and n ϭ 47, 60 Ϯ 5 m, and 167-25 m for the low-PIP control group. V c /V w was significantly greater for the high-PIP injury (3.3-fold), ATK (2.2-fold), and COX ϩ LOX ϩ P-450 (2.1-fold) groups than for the low-PIP control group. V c /V w was also significantly higher for the high-PIP injury group than for the ATK group.
DISCUSSION
In the present study, we determined the role of cPLA 2 and the downstream products of AA metabolism in the increases in permeability induced by acute high-PIP ventilation in isolated mouse lungs. We previously reported that ATK, an inhibitor of cPLA 2 , attenuated the VILI-induced increase in permeability in intact mouse lungs (46) . The increase in vascular permeability due to high-volume ventilation appears rapidly, before significant increases in cytokines (36, 45) . The major new findings of the present study are as follows. 1) cPLA 2 inhibition also significantly attenuated the high-PIP-induced increase in vascular permeability in isolated mouse lungs. 2) Permeability was not prevented by blockade of only one or two of these downstream pathways, but a combination of inhibitors simultaneously targeting all three downstream pathways of AA metabolism attenuated the increase in permeability and edema formation by approximately the same amount as inhibition of cPLA 2 . These findings suggest that cPLA 2 plays a crucial role in the pathogenesis of acute VILI and that multiple downstream products of AA have mutually potentiating effects to produce this increase in permeability.
Isolated lung preparations have become a standard tool for measuring rapid increases in lung vascular permeability. K fc is a measure of endothelial hydraulic conductivity independent of filtration pressure, because filtration rate is normalized to microvascular pressure and lung weight (surface area) (5, 30, 33) . Since W/D and, to some extent, the convective transport of albumin into the alveoli are dependent on the filtration pressure and the time for filtration (33, 40) , K fc is a more sensitive indicator of endothelial barrier properties. In addition, filtration and K fc change as transcapillary pore radius to the fourth power, whereas BALF albumin fluxes vary as the pore radius Values are means Ϯ SE, expressed in cmH2O ⅐ l Ϫ1 ⅐ min ⅐ 100 g Ϫ1 . Rt, total pulmonary vascular resistance; Ra, pulmonary arterial resistance; Rv, pulmonary venous resistance. *P Ͻ 0.05 vs. baseline within the same group. †P Ͻ 0.05 vs. low-PIP control in the same time period. squared (9, 40) . Using K fc measurements, we could discriminate relatively modest increases in vascular permeability. The magnitudes of the differences between high-and low-PIP ventilation and the effect of inhibitors were much greater for K fc measurements than BALF albumin concentrations or W/D (see RESULTS) . In contrast to BALF albumin concentrations or W/D, K fc measurements are independent of time and vascular pressure effects. This resulted in a better statistical resolution of differences between the high-PIP injury group and the injury-inhibitory effects in the low-PIP control, ATK, and COX ϩ LOX ϩ P-450 groups. K fc measurements indicated that the ATK and COX ϩ LOX ϩ P-450 groups significantly protected against the increased permeability of high-PIP ventilation, even though these K fc values were significantly higher than K fc of the low-PIP group. BALF albumin was also significantly lower in the ATK and COX ϩ LOX ϩ P-450 groups than in the high-PIP group but significantly lower in the ATK group than in the COX ϩ LOX ϩ P-450 group. W/D values were statistically significantly different in the high-and low-PIP groups, but W/D values in the ATK group were not statistically greater than those in the low-PIP group. However, morphometric estimates of cuff volumes did indicate statistically significantly smaller volumes in the ATK and COX ϩ LOX ϩ P-450 groups than in the high-PIP group. Since we assessed lung injury using W/D and BALF albumin and protein concentration in our previous study of cPLA 2 inhibition in intact mice (46), we sought to confirm our previous observation that inhibition of cPLA 2 could inhibit the increased permeability induced by VILI by measuring K fc in isolated mouse lungs (46) . Fig. 4 . Arachidonic acid metabolites in bronchoalveolar lavage fluid from all groups determined using an ELISA for 6-keto-PGF1␣ (A) and cysteinyl leukotrienes (B). *P Ͻ 0.05 vs. high-PIP injury group. #P Ͻ 0.05 vs. COX group. Fig. 3 . Representative Western blots of phosphorylated cytosolic phospholipase A2 (cPLA2) in lung tissue homogenates in low-PIP control and high-PIP injury groups. A: total and phosphorylated cPLA2 in lung tissue homogenates. B: phosphorylated cPLA2 in membrane and cytosol fractions of lung tissue homogenates. *P Ͻ 0.05 vs. low-PIP control group. cPLA 2 is an 85-kDa protein that is widely distributed in cells and is activated by submicromolar intracellular Ca 2ϩ concentrations and phosphorylation by activated MAPK during high-PIP ventilation (20, 47) . Phosphorylated cPLA 2 then moves to the cell membrane to liberate AA (23) . Ca 2ϩ and MAPK activation increase in stretched endothelial cell monolayers as well as in in situ endothelial and epithelial cells in intact lungs during overdistension (4, 27) . PLA 2 activation has also been reported in endothelial cells in culture (35) and in intact blood-perfused lungs after mechanical stress (19) . In the present study, cPLA 2 phosphorylation was increased by high-PIP ventilation compared with low-PIP ventilation in mouse lungs, which, together with the increases in downstream COX and LOX, indicates activation of cPLA 2 by high-PIP ventilation. A second type of PLA 2 , the lower-molecular-weight secretory phospholipase A 2 (sPLA 2 ), is normally present in some lung cell types, but a spontaneous disruption of the sPLA 2 gene in exon 3 in inbred strains of C57BL/6 mice (18) precludes its contribution to the PLA 2 activity in the present studies. A third type, the Ca 2ϩ -independent form of PLA 2 (iPLA 2 ) is primarily a housekeeping enzyme for specialized phospholipids; in the mouse, it is present primarily in the digestive tract and only in trace amounts in the lung (23) . A fourth group of proteins with PLA 2 activity are the PAF acetyl hydrolases, which have substrate specificity for PAF but do not appear to be involved in AA release (6) . Although the ATK dose used in the present study also inhibits iPLA 2 , the contribution of iPLA 2 to the lung responses described here is likely to be small. ATK may also have some inhibitory effects on the COX pathway, but since this pathway is downstream of PLA 2 , the primary effect of ATK in the present study is considered to be on cPLA 2 (6) . The major downstream routes of AA metabolism include oxygenation by COX, LOX, or P-450 monooxygenases (6). Isolated lung studies and endothelial and epithelial monolayer experiments provide putative evidence that VILI is initiated by mechanogated Ca 2ϩ entry through nonselective cation channels (28) . Parker et al. (31, 34) reported that high-PIPinduced increases in filtration coefficients were attenuated using gadolinium chloride, a stretch-activated cation channel and nonspecific Ca 2ϩ channel blocker. Recent evidence indicates that the mechanogated channel that initiates the increased vascular permeability of VILI is the TRPV4 channel protein (15, 38) . These channels were activated by mechanical stress and secondarily by mechanical stimulation of PLA 2 activity and subsequent AA release (43) . P-450 derivatives of AA metabolism, in particular 5,6-EET, strongly activate the TRPV4 channels (44). Alvarez et al. (1, 2) reported that infusion of 5,6-and 14,15-EET increased K fc in isolated mouse and rat lungs, and this increase was blocked by ruthenium red, a TRP channel inhibitor. Recently, Hamanaka et al. (15) observed that the high-PIP-induced permeability increases in isolated mouse lungs were blocked by the TRPV channel inhibitor ruthenium red, methanandamide, an inhibitor of AA production, and miconazole, a P-450 inhibitor, and was absent in lungs from TRPV4-knockout mice. Thus metabolites of the P-450 pathway are major contributors to the increased vascular permeability induced by VILI, apparently by facilitating Ca 2ϩ entry through stretch-activated cation channels.
Measurement of the stable product of PGI 2 degradation, 6-keto-PGF 1␣ , and the cysteinyl LTs indicates that high-PIP ventilation significantly increased COX and LOX products in lavage fluid compared with low-PIP ventilation. Blockade of PLA 2 during high-PIP ventilation attenuated the products of COX and LOX pathways and significantly attenuated the K fc increase. Although inhibition of the COX or LOX pathways alone preferentially reduced the products of the inhibited pathway, separate pathway inhibition was less effective in reducing the K fc increase after high-PIP ventilation. The inhibitory responses in these studies and previous studies indicate that the doses of inhibitors were sufficient to block the target pathways. Nagase et al. (24) found that pretreatment with only 20 mg/kg of the slow-binding, but effective, PLA 2 inhibitor ATK was sufficient to significantly reduce BALF LTB 4 , TXB 2 , and the cysteinyl LTs LTC 4 , LTD 4 , and LTE 4 in a mouse model of LPS-zymosan lung injury. Similarly, the dose of 17-octadecynoic acid would be expected to effectively inhibit P-450, because its IC 50 values for inhibition of -hydroxylation and epoxidation were 7 and 5 M, respectively (42) . Effective doses of ibuprofen and nordihydroguaiaretic acid, the nonselective inhibitors of the COX and LOX pathways, were also used.
Lipid mediators are known to play a significant role in lung endothelial and alveolar epithelial barrier function (24, 25) . We hypothesized that many of the endogenous levels of the downstream products of AA metabolism have the potential to increase vascular permeability. Release of PGE 2 , PGI 2 , and TXA 2 is edemagenic during acute lung inflammation, as is release of nonenzymatically produced prostanes (29) . Release of TXB 2 , the stable product of TXA 2 , was significantly greater in the perfusate in isolated rabbit lungs after high-PIP ventilation than after low-PIP ventilation (12) . On the other hand, there were no detectable levels of TX, LTB 4 , and PGE 2 and no change in COX-2 mRNA expression in the perfusate in isolated mouse lung with negative-or positive-pressure hyperventilation (41) . The present study demonstrated that inhibition of all three major pathways in the COX ϩ LOX ϩ P-450 group, but not inhibition of only two pathways in the LOX ϩ P-450 group, attenuated the increase in permeability. This finding suggests that the COX pathway might contribute to VILIinduced increases in permeability, but the COX inhibitor alone did not attenuate the increase in permeability, even though 6-keto-PGF 1␣ was significantly decreased in lavage fluid in all COX inhibitor-treated groups. Thus inhibition of mediators derived from a single pathway had no effect on the magnitude of the increased permeability, even though many of these mediators infused in very high concentrations have the potential to increase vascular permeability. Potentiation of effects of multiple mediators may occur through activation of multiple second messenger pathways, which together initiate the permeability response (16) . Another mechanism may be competition for AA substrate between the various AA pathways. For example, in the presence of COX blockade, as in the COX group, AA metabolites appear to be shifted toward the LOX and P-450 pathways (10) .
Studies of patients with ARDS indicated markedly elevated levels of LTs in pulmonary edema fluid compared with edema fluid from patients with hydrostatic pulmonary edema (21) . LTB 4 , a potent neutrophil chemoattractant, appears to have a significant role in high-PIP injury. Recently, Caironi et al. (8) demonstrated that high-tidal volume ventilation impaired the vasoconstriction response, increased alveolar epithelial permeability, elevated BALF levels of cysteinyl LTs (LTC 4 , LTD 4 , and LTE 4 ), and increased influx of neutrophils into the air spaces. Increases in these LTs were absent in 5-LOX-knockout mice under the same conditions (8) . Even though physiological buffer without blood was used in the present study, the LOX inhibitor significantly inhibited lavage LT concentrations and partially attenuated the increase in permeability, possibly an indication of a neutrophil-independent mechanism of injury, such as an altered epithelial fluid clearance (37) . However, nonspecific LOX inhibition may be protective as a result of inhibition of the 5-LOX pathway production of cysteinyl LTs and the 12-LOX production of 12-HETE but will also inhibit 15-LOX production of anti-inflammatory lipoxins (6) .
PAF, another of the downstream products generated from phospholipids by cPLA 2 , may contribute to the increases in vascular permeability. PAF-induced edema formation proceeds by two distinct mechanisms, which are mediated by the inositol 1,4,5-trisphosphate receptor or PGE 2 , a COX metabolite (10, 14) . In the present study, there were no significant differences in K fc or W/D between the ATK group and the COX ϩ LOX ϩ P-450 group. Although the combination of the all inhibitors of COX, LOX, and P-450 pathways would not inhibit PAF synthesis directly, the COX inhibitor may have reduced the PAF contribution to the increased K fc , such that K fc in the COX ϩ LOX ϩ P-450 group was similar to that in the ATK group.
The decreases in vascular resistance indicated the wellknown effects of recruitment and distension of microvessels on vascular resistance (30) . In the present study, R t , especially R v , in the low-PIP control group decreased significantly at the end of the experiments. In the other groups, R t decreased transiently at 50 min and increased again at the end of the experiment. Mechanical compression of small vessels by edema may have induced the increased R t in those groups (32) .
Mediators such as TX and PAF are well-known vasoconstrictors of the pulmonary artery (10) . Because the COX inhibitor ibuprofen can block the vasoconstrictor effects of TX, as well as the vasodilator effects of PGI 2 , these opposing effects could cancel one another and result in the lack of a significant difference in R t between groups with or without ibuprofen.
In conclusion, cPLA 2 activation appears to contribute to the rapid increase in lung vascular permeability of VILI in mice through numerous pathways. The high-pressure lung distension used in the present study induced increases in the levels of various downstream products of AA metabolism, which appear to potentiate each other to increase lung vascular permeability.
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